$432 Million is the total value of COMMODORE CAPITAL LP's 25 reported holdings in Q4 2021. The portfolio turnover from Q3 2021 to Q4 2021 was 34.5% .
| Value | Shares | ↓ Weighting | ||||||
|---|---|---|---|---|---|---|---|---|
| ISEE | Buy | IVERIC BIO INC | $53,791,000 | +20.4% | 3,217,163 | +17.0% | 12.46% | +5.8% |
| MRUS | Buy | MERUS N V | $47,665,000 | +201.7% | 1,498,890 | +108.7% | 11.04% | +165.0% |
| ACRS | Buy | ACLARIS THERAPEUTICS INC | $38,856,000 | -1.4% | 2,672,346 | +22.0% | 9.00% | -13.4% |
| XENE | Buy | XENON PHARMACEUTICALS INC | $34,056,000 | +284.6% | 1,090,126 | +88.1% | 7.89% | +237.9% |
| CYTK | Sell | CYTOKINETICS INC | $32,113,000 | +12.8% | 704,537 | -11.6% | 7.44% | -0.9% |
| PTGX | Buy | PROTAGONIST THERAPEUTICS INC | $27,551,000 | +212.2% | 805,573 | +61.7% | 6.38% | +174.2% |
| BLU | New | BELLUS HEALTH INC NEW | $25,153,000 | – | 3,124,613 | +100.0% | 5.83% | – |
| COGT | Buy | COGENT BIOSCIENCES INC | $19,574,000 | +21.7% | 2,281,315 | +19.3% | 4.53% | +6.9% |
| CBAY | Buy | CYMABAY THERAPEUTICS INC | $18,319,000 | +20.4% | 5,419,896 | +30.0% | 4.24% | +5.7% |
| VRDN | Buy | VIRIDIAN THERAPEUTICS INC | $16,759,000 | +52.6% | 847,683 | +27.0% | 3.88% | +34.0% |
| STSA | Buy | SATSUMA PHARMACEUTICALS INC | $16,701,000 | +14.9% | 3,711,286 | +19.0% | 3.87% | +0.9% |
| VTGN | Buy | VISTAGEN THERAPEUTICS INC | $16,507,000 | +17.6% | 8,464,999 | +65.2% | 3.82% | +3.3% |
| CCCC | C4 THERAPEUTICS INC | $15,491,000 | -27.9% | 481,094 | 0.0% | 3.59% | -36.7% | |
| CELC | CELCUITY INC | $12,141,000 | -26.7% | 920,464 | 0.0% | 2.81% | -35.6% | |
| TCDA | New | TRICIDA INC | $11,922,000 | – | 1,247,043 | +100.0% | 2.76% | – |
| TENAYA THERAPEUTICS INC | $9,739,000 | -8.2% | 513,930 | 0.0% | 2.26% | -19.4% | ||
| ALLK | New | ALLAKOS INC | $7,985,000 | – | 815,667 | +100.0% | 1.85% | – |
| KALV | KALVISTA PHARMACEUTICALS INC | $4,135,000 | -24.2% | 312,553 | 0.0% | 0.96% | -33.4% | |
| KRON | KRONOS BIO INC | $4,061,000 | -35.2% | 298,839 | 0.0% | 0.94% | -43.0% | |
| DYN | DYNE THERAPEUTICS INC | $3,628,000 | -26.8% | 305,125 | 0.0% | 0.84% | -35.7% | |
| IVA | INVENTIVA SAads | $3,588,000 | -3.5% | 262,658 | 0.0% | 0.83% | -15.3% | |
| GNCA | GENOCEA BIOSCIENCES INC | $3,573,000 | -39.6% | 3,079,756 | 0.0% | 0.83% | -46.9% | |
| MREO | Sell | MEREO BIOPHARMA GROUP PLCads | $3,128,000 | -34.5% | 1,954,970 | -0.9% | 0.72% | -42.5% |
| PMVP | PMV PHARMACEUTICALS INC | $2,888,000 | -22.5% | 125,000 | 0.0% | 0.67% | -31.9% | |
| BLSA | BCLS ACQUISITION CORP | $2,450,000 | -1.6% | 250,000 | 0.0% | 0.57% | -13.6% | |
| SBTX | Exit | SILVERBACK THERAPEUTICS INC | $0 | – | -97,143 | -100.0% | -0.26% | – |
| Exit | ASTRIA THERAPEUTICS INC | $0 | – | -239,270 | -100.0% | -0.56% | – | |
| RVMD | Exit | REVOLUTION MEDICINES INC | $0 | – | -226,228 | -100.0% | -1.64% | – |
| IOVA | Exit | IOVANCE BIOTHERAPEUTICS INC | $0 | – | -362,869 | -100.0% | -2.36% | – |
| CLDX | Exit | CELLDEX THERAPEUTICS INC NEW | $0 | – | -248,207 | -100.0% | -3.53% | – |
| KURA | Exit | KURA ONCOLOGY INC | $0 | – | -999,433 | -100.0% | -4.94% | – |
| DRNA | Exit | DICERNA PHARMACEUTICALS INC | $0 | – | -1,292,251 | -100.0% | -6.87% | – |
Original filings
The following EDGAR filing(s) were analyzed to create this report:
- View 13F-HR filed 2022-02-14
Top long-term holdings
| Name | Quarters owned | Latest quarter owned | Max weighting |
|---|---|---|---|
| XENON PHARMACEUTICALS INC | 12 | Q3 2023 | 10.3% |
| COGENT BIOSCIENCES INC | 12 | Q3 2023 | 10.4% |
| VIRIDIAN THERAPEUTICS INC | 11 | Q3 2023 | 8.9% |
| CYMABAY THERAPEUTICS INC | 11 | Q2 2023 | 5.4% |
| KURA ONCOLOGY INC | 11 | Q3 2023 | 7.1% |
| CELLDEX THERAPEUTICS INC NEW | 11 | Q3 2023 | 3.8% |
| ACLARIS THERAPEUTICS INC | 10 | Q1 2023 | 10.4% |
| CELCUITY INC | 10 | Q3 2023 | 7.3% |
| KALVISTA PHARMACEUTICALS INC | 10 | Q2 2023 | 2.2% |
| MERUS N V | 9 | Q3 2023 | 12.5% |
View COMMODORE CAPITAL LP's complete holdings history.
Latest significant ownerships (13-D/G)
| Filed | Shares | Percentage | |
|---|---|---|---|
| Ambrx Biopharma Inc. | April 27, 2023 | 31,181,983 | 8.1% |
| BELLUS Health Inc. | March 30, 2023 | 6,579,359 | 5.2% |
| IMARA Inc. | February 21, 2023 | 2,840,754 | 10.8% |
| Karyopharm Therapeutics Inc. | February 14, 2023 | 1,935,609 | 1.7% |
| VistaGen Therapeutics, Inc.Sold out | February 14, 2023 | 0 | 0.0% |
| Satsuma Pharmaceuticals, Inc.Sold out | November 16, 2022 | 0 | 0.0% |
| GENOCEA BIOSCIENCES, INC. | February 14, 2022 | 3,079,756 | 5.4% |
View COMMODORE CAPITAL LP's complete significant-ownership history.
Latest filings
| Type | Filed |
|---|---|
| SC 13G | 2024-04-19 |
| SC 13G | 2024-03-21 |
| 13F-HR/A | 2024-02-14 |
| 13F-HR | 2024-02-14 |
| SC 13G/A | 2024-02-14 |
| SC 13G/A | 2024-02-14 |
| SC 13G/A | 2024-02-14 |
| SC 13G/A | 2024-02-14 |
| SC 13G/A | 2024-02-14 |
| SC 13G/A | 2024-02-14 |
View COMMODORE CAPITAL LP's complete filings history.
All filings
- Holdings (13F-HR)
- Significant ownership (13-D/G)
- Insider transactions (4, 5, 6)
- Events (8-K)
- Shareholder votes (proxy)
View complete filings history.